Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis

- Patient has completed (i.e. not dropped out of) the DE013 study or fulfills criteria 2-12 - Patients 18 years of age or older - Female is either not childbearing, defined as post-menopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if childbearing potential, practicing an acceptable method of birth control - Female of childbearing potential must have a negative serum pregnancy test prior to first dose of adalimumab - Diagnosis of active RA defined by >= 5 swollen joints and one of the following: - Positive RF - One or more joint erosions present of x-ray - HAQ score > 1

- Patient has failed 2 or more biologics - Patient who had previous treatment with cyclophosphamide and chlorambucil - Previous treatment with total lymphoid irradiation or anti-CD4 or CAMPATH 1H monoclonal antibody resulting in presistent CD4 lymphopenia (CD4 lymphocytes +< 500/mm3) - History of cancer within the past 10 years unless successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix - History of malignant lymphoma or leukemia regardless of treatment